Prolactin-releasing peptide: a new tool for obesity treatment
Jazyk angličtina Země Anglie, Velká Británie Médium print
Typ dokumentu časopisecké články, přehledy, práce podpořená grantem
PubMed
27418033
DOI
10.1530/joe-16-0046
PII: 230/2/R51
Knihovny.cz E-zdroje
- Klíčová slova
- GPR10, anorexigenic, lipidization, mice, obesity, prolactin-releasing peptide,
- MeSH
- hormon uvolňující prolaktin analogy a deriváty terapeutické užití MeSH
- látky proti obezitě farmakologie terapeutické užití MeSH
- lékové transportní systémy * MeSH
- lidé MeSH
- obezita farmakoterapie MeSH
- regulace chuti k jídlu * MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- Názvy látek
- hormon uvolňující prolaktin MeSH
- látky proti obezitě MeSH
Obesity is an escalating epidemic, but an effective noninvasive therapy is still scarce. For obesity treatment, anorexigenic neuropeptides are promising tools, but their delivery from the periphery to the brain is complicated because peptides have a low stability and limited ability to cross the blood-brain barrier. In this review, we summarize results of several studies with our newly designed lipidized analogs of prolactin-releasing peptide (PrRP). PrRP is involved in feeding and energy balance regulation as demonstrated by obesity phenotypes of both PrRP- and PrRP-receptor-knockout mice. Lipidized PrRP analogs showed binding affinity and signaling in PrRP receptor-expressing cells similar to natural PrRP. Moreover, these analogs showed high binding affinity also to anorexigenic neuropeptide FF (NPFF)-2 receptor. Acute peripheral administration of myristoylated and palmitoylated PrRP analogs to mice and rats induced strong and long-lasting anorexigenic effects and neuronal activation in the brain areas involved in food intake regulation. Two-week-long subcutaneous administration of palmitoylated PrRP31 and myristoylated PrRP20 lowered food intake, body weight, improved metabolic parameters and attenuated lipogenesis in mice with diet-induced obesity. A strong anorexigenic, body weight-reducing and glucose tolerance-improving effect of palmitoylated-PrRP31 was shown also in diet-induced obese rats after its repeated 2-week-long peripheral administration. Thus, the strong anorexigenic and body weight-reducing effects of palmitoylated PrRP31 and myristoylated PrRP20 make these analogs attractive candidates for antiobesity treatment. Moreover, PrRP receptor might be a new target for obesity therapy.
Citace poskytuje Crossref.org
Lipidization as a tool toward peptide therapeutics
NPFFR2-deficient mice fed a high-fat diet develop strong intolerance to glucose
Metabolomic Study of Aging in fa/fa Rats: Multiplatform Urine and Serum Analysis
Prolactin-Releasing Peptide: Physiological and Pharmacological Properties